Relatlimab

Source: Wikipedia, the free encyclopedia.
Relatlimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetLymphocyte activation gene-3 (LAG-3)
Clinical data
Other namesBMS-986016, relatlimab-rmbw
License data
Antineoplastic
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6472H9922N1710O2024S38
Molar mass145288.79 g·mol−1

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[3][4] It is used in combination with nivolumab to treat melanoma.[2][5]

Relatlimab is a

Bristol-Myers Squibb.[2][5] It is made using Chinese hamster ovary cells.[2]

History

As of 2018[update], relatlimab is undergoing

III trials.[6]

The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[2][5]

Names

Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[7][8][9]

References

  1. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
  2. ^ a b c d e f "Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.
  3. ISBN 978-1-00-047185-4
    .
  4. S2CID 245407697
    .
  5. ^ a b c d "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.
  6. ^ Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
  7. ^ "Relatlimab". American Medical Association. Retrieved 22 March 2022.
  8. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
  9. hdl:10665/330896
    .


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Relatlimab&oldid=1193320967"